A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Registration Number
- NCT06065540
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 2734
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening.
- Stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors.
- Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening.
- Body Mass Index (BMI) greater than or equal to 25 kilogram per square metre ( kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
- Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square metre (mL/min/1.73 m^2) as determined by central laboratory at screening.
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CagriSema 2.4 mg/2.4 mg Cagrilintide Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks. CagriSema 2.4 mg/2.4 mg Semaglutide Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks. CagriSema 1.0 mg/1.0 mg Cagrilintide Participants will receive once-weekly s.c injections of 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks. CagriSema 1.0 mg/1.0 mg Semaglutide Participants will receive once-weekly s.c injections of 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks. Semaglutide 2.4 mg Semaglutide Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 68 weeks. Semaglutide 1.0 mg Semaglutide Participants will receive once-weekly s.c injection of 1.0 mg semaglutide for 68 weeks. Cagrilintide 2.4 mg Cagrilintide Participants will receive once-weekly s.c injection of 2.4 mg cagrilintide for 68 weeks. Placebo 2.4 mg/2.4 mg Placebo cagrilintide Participants will receive once-weekly s.c injection of placebo matched to 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks. Placebo 2.4 mg/2.4 mg Placebo semaglutide Participants will receive once-weekly s.c injection of placebo matched to 2.4 mg cagrilintide and 2.4 mg semaglutide for 68 weeks. Placebo 1.0 mg/1.0 mg Placebo cagrilintide Participants will receive once-weekly s.c injection of placebo matched to 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks. Placebo 1.0 mg/1.0 mg Placebo semaglutide Participants will receive once-weekly s.c injection of placebo matched to 1.0 mg cagrilintide and 1.0 mg semaglutide for 68 weeks.
- Primary Outcome Measures
Name Time Method CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Change in glycated haemoglobin (HbA1c) From baseline (week 0) to end of treatment (week 68) Measured in percentage-points.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Relative change in body weight From baseline (week 0) to end of treatment (week 68) Measured in percentage.
- Secondary Outcome Measures
Name Time Method CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 (mmol/L) (70-140 mg/dL) From baseline (week -3) to end of treatment (week 68) Measured in percentage-points.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Systolic Blood Pressure (SBP) From baseline (week 0) to end of treatment (week 68) Measured in millimeters of mercury (mmHg).
CagriSema 2.4 mg/2.4 mg versus cagrilintide 2.4 mg: Change in HbA1c From baseline (week 0) to end of treatment (week 68) Measured in percentage-points.
CagriSema 2.4 mg/2.4 mg versus cagrilintide 2.4 mg: Relative change in body weight From baseline (week 0) to end of treatment (week 68) Measured in percentage.
CagriSema 2.4 mg/2.4 mg versus semaglutide 1.0 mg: Change in HbA1c From baseline (week 0) to end of treatment (week 68) Measured in percentage-points.
CagriSema 2.4 mg/2.4 mg versus semaglutide 1.0 mg: Relative change in body weight From baseline (week 0) to end of treatment (week 68) Measured in percentage.
Cagrilintide 2.4 mg versus placebo: Change in HbA1c From baseline (week 0) to end of treatment (week 68) Measured in percentage-points.
Cagrilintide 2.4 mg versus placebo: Relative change in body weight From baseline (week 0) to end of treatment (week 68) Measured in percentage.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of greater than or equal to (>=) 10 percent (%) weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participants.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of >= 15 % weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participants.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of >= 20 % weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participants.
CagriSema (pooled doses) versus semaglutide (pooled doses): Continuous Glucose Monitoring (CGM) - Change in Time in Range (TIR) 3.9-10.0 millimoles per litre (mmol/L) (70-180 milligrams per decilitre [mg/dL]) From baseline (week -3) to end of treatment (week 68) Measured in percentage-points.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in triglycerides From baseline (week 0) to end of treatment (week 68) Measured as ratio of triglycerides.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols From baseline (week 0) to end of treatment (week 68) Measured as ratio of non-HDL cholesterol.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) From baseline (week -3) to end of treatment (week 68) Measured in percentage-points.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP) From baseline (week 0) to end of treatment (week 68) Measured as ratio of hsCRP.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Fasting Plasma Glucose (FPG) From baseline (week 0) to end of treatment (week 68) Measured in mmol/L.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol]) At end of treatment (week 68) Measured as count of participants.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol) At end of treatment (week 68) Measured as count of participants.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL) From baseline (week 0) to end of treatment (week 68) Measured in percentage-points.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL) From baseline (week 0) to end of treatment (week 68) Measured in percentage-points.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): CGM - Within-day glycaemic variability (% coefficient of variation [CV]) At end of treatment (week 68) Measured in percentage.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg versus 1.0 mg): Achievement of ≥ 5 % weight reduction From baseline (week 0) to end of treatment (week 68) Measured as count of participants.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in waist circumference From baseline (week 0) to end of treatment (week 68) Measured in centimetre.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Diastolic Blood Pressure (DBP) From baseline (week 0) to end of treatment (week 68) Measured in mmHg.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in total cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio of total cholesterol.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in HDL cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio of HDL cholesterol.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in low-density lipoprotein (LDL) cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio of LDL cholesterol.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol From baseline (week 0) to end of treatment (week 68) Measured as ratio of VLDL.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Ratio to baseline in free fatty acids From baseline (week 0) to end of treatment (week 68) Measured as ratio of free fatty acids.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Short Form (SF)-36v score- Physical component summary score From baseline (week 0) to end of treatment (week 68) SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Physical component summary score range from 6.1 to 79.7, with higher scores indicating better functional health and well-being.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in SF-36v2 score- Mental component summary score From baseline (week 0) to end of treatment (week 68) SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Mental component summary score range from -3.8 to 78.7, with higher scores indicating better functional health and well-being.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score From baseline (week 0) to end of treatment (week 68) DTSQc measures treatment satisfaction and diabetes-specific quality of life (QoL). The measure consists of 8 items yielding 1 global score and 2 single item scores. Total treatment satisfaction scores range from 0-36, with higher scores indicating greater satisfaction; the perceived frequency of hyperglycemia/hypoglycemia items are scored separately, with lower scores indicating better perceived blood glucose control.
CagriSema versus semaglutide (2.4 mg/2.4 mg versus 2.4 mg and 1.0 mg/1.0 mg vs 1.0 mg): Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score From baseline (week 0) to end of treatment (week 68) TRIM-D measures impact of diabetes treatment. The measure consists of 28 items yielding 5 domain scores and a total score. The scores were transformed to a 0-100 scale with higher scores indicating a better health state.
CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of treatment emergent adverse events (TEAEs) From baseline (week 0) to end of study (week 75) Measured as count of events.
CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter) From baseline (week 0) to end of study (week 75) Measured as count of episodes.
CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) versus semaglutide (2.4 mg and 1.0 mg), placebo and cagrilintide 2.4 mg: Number of severe hypoglycaemic episodes (level 3) From baseline (week 0) to end of study (week 75) Measured as count of episodes. Hypoglycaemia episodes (level 3) are the episodes associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold.
Trial Locations
- Locations (343)
Momentum Clinical Research Darlinghurst
🇦🇺Darlinghurst, New South Wales, Australia
Beijing Friendship Hospital, Capital Medical University-Endocrinology
🇨🇳Beijing, Beijing, China
Chinese People's Liberation Army General Hospital-Endocrinology
🇨🇳Beijing, Beijing, China
Huaihe Hospital of Henan University-Endocrinology
🇨🇳Kaifeng, Henan, China
Universitätsklinikum Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck
🇩🇪Lübeck, Germany
Univ of Alabama_Birmingham
🇺🇸Birmingham, Alabama, United States
Cahaba Research
🇺🇸Pelham, Alabama, United States
Velocity Clinical Research-Phoenix
🇺🇸Phoenix, Arizona, United States
Synexus Rsch /Cnt Phnx Med C
🇺🇸Phoenix, Arizona, United States
Arkansas Clinical Research
🇺🇸Little Rock, Arkansas, United States
Velocity Clinical Res-Banning
🇺🇸Banning, California, United States
Velocity Clin Res-Chula Vista
🇺🇸Chula Vista, California, United States
John Muir Physicians Network
🇺🇸Concord, California, United States
Headlands Research California, LLC
🇺🇸Escondido, California, United States
Velocity Clin Res Gardena
🇺🇸Gardena, California, United States
Velocity Clin Res San Diego
🇺🇸La Mesa, California, United States
Loma Linda Univ Hlth Cr Endo
🇺🇸Loma Linda, California, United States
Facey Medical Foundation
🇺🇸Mission Hills, California, United States
Desert Oasis Hlthcr Med Group
🇺🇸Palm Springs, California, United States
Velocity Clin Res- San Bern
🇺🇸San Bernardino, California, United States
Linda Vista Health Care Ctr
🇺🇸San Diego, California, United States
Velocity Clin Res Santa Ana
🇺🇸Santa Ana, California, United States
Premier Medical Center, Inc.
🇺🇸Toluca Lake, California, United States
Velocity Clin Res - Panorama
🇺🇸Van Nuys, California, United States
Optumcare Colorado Springs
🇺🇸Colorado Springs, Colorado, United States
Northeast Research Institute
🇺🇸Jacksonville, Florida, United States
Clinical Trial Services Corp
🇺🇸Miami, Florida, United States
Bioclinical Research Alliance
🇺🇸Miami, Florida, United States
New Horizon Research Center
🇺🇸Miami, Florida, United States
South Broward Research LLC
🇺🇸Miramar, Florida, United States
West Orange Endocrinology
🇺🇸Ocoee, Florida, United States
Optimal Research Sites
🇺🇸Orange City, Florida, United States
AdventHealth Diab Inst
🇺🇸Orlando, Florida, United States
Hope Clin Res & Wellness
🇺🇸Conyers, Georgia, United States
East Coast Institute for Res
🇺🇸Macon, Georgia, United States
Urban Family Practice Assoc
🇺🇸Marietta, Georgia, United States
Endocrine Research Solutions, Inc.
🇺🇸Roswell, Georgia, United States
Endocrine Research Solutions
🇺🇸Roswell, Georgia, United States
St. Luke's Health System
🇺🇸Boise, Idaho, United States
Solaris Clinical Research
🇺🇸Meridian, Idaho, United States
Cedar-Crosse Research Center
🇺🇸Chicago, Illinois, United States
Clinical Invest Special_Gurnee
🇺🇸Gurnee, Illinois, United States
Endeavor Health
🇺🇸Skokie, Illinois, United States
Evanston Premier Hlthcr Res
🇺🇸Skokie, Illinois, United States
Iowa Diabetes & Endo Res Ctr
🇺🇸West Des Moines, Iowa, United States
Alliance for Multispec Res
🇺🇸Norman, Oklahoma, United States
Cotton-O'Neil Diab & Endo Ctr
🇺🇸Topeka, Kansas, United States
Velocity Clin Res Lafayette
🇺🇸Lafayette, Louisiana, United States
BTC of New Bedford, LLC
🇺🇸New Bedford, Massachusetts, United States
Velocity Clin Res Gulfport
🇺🇸Gulfport, Mississippi, United States
Diabetes & Endo Specialists Inc
🇺🇸Chesterfield, Missouri, United States
Premier Research Inc.
🇺🇸Trenton, New Jersey, United States
Velocity Clin Res Albuquerque
🇺🇸Albuquerque, New Mexico, United States
Albany Medical College - Endo
🇺🇸Albany, New York, United States
Velocity Clin Res Syracuse
🇺🇸East Syracuse, New York, United States
Southgate Medical Group, LLP
🇺🇸West Seneca, New York, United States
Great Lakes Medical Research
🇺🇸Westfield, New York, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
PharmQuest Life Sciences LLC
🇺🇸Greensboro, North Carolina, United States
Carteret Medical Group
🇺🇸Morehead City, North Carolina, United States
Piedmont Healthcare/Research
🇺🇸Statesville, North Carolina, United States
Accellacare
🇺🇸Wilmington, North Carolina, United States
Radiant Research Inc. - Akron
🇺🇸Akron, Ohio, United States
Aventiv Research
🇺🇸Dublin, Ohio, United States
Clinical Res Collaborative
🇺🇸Cumberland, Rhode Island, United States
Velocity Clin Res Providence
🇺🇸East Greenwich, Rhode Island, United States
AnMed Health IMA
🇺🇸Anderson, South Carolina, United States
Synexus Clin Res US-Anderson
🇺🇸Anderson, South Carolina, United States
Velocity Clinical Res-Anderson
🇺🇸Anderson, South Carolina, United States
Velocity Clin Res Gaffney
🇺🇸Gaffney, South Carolina, United States
Spartanburg Medical Research
🇺🇸Spartanburg, South Carolina, United States
Velocity Clin Res Spartanburg
🇺🇸Spartanburg, South Carolina, United States
Holston Medical Group Pc
🇺🇸Bristol, Tennessee, United States
Holston Medical Group
🇺🇸Kingsport, Tennessee, United States
Clinical Research Associates
🇺🇸Nashville, Tennessee, United States
Arlington Family Res. Ctr Inc
🇺🇸Arlington, Texas, United States
Velocity Clin Res Austin
🇺🇸Austin, Texas, United States
Velocity Clinical Res-Dallas
🇺🇸Dallas, Texas, United States
North Texas Endocrine Center
🇺🇸Dallas, Texas, United States
Synexus Clin Res Dallas
🇺🇸Dallas, Texas, United States
Cedar Health Research
🇺🇸Dallas, Texas, United States
Juno Research, LLC_Houston
🇺🇸Houston, Texas, United States
Synergy Groups Medical
🇺🇸Houston, Texas, United States
PlanIt Research, PLLC
🇺🇸Houston, Texas, United States
Medical Colleagues-Texas LLP
🇺🇸Katy, Texas, United States
Sante Clinical Research
🇺🇸Kerrville, Texas, United States
Discovery MMS Services, INC
🇺🇸Missouri City, Texas, United States
AES San Antonio
🇺🇸San Antonio, Texas, United States
Univ Of Texas Hlth Science Cntr
🇺🇸San Antonio, Texas, United States
NE Clin Res of San Antonio
🇺🇸San Antonio, Texas, United States
Consano Clinical Research, LLC
🇺🇸Shavano Park, Texas, United States
DM Clin Rsrch/Fam Diag Clinic
🇺🇸Tomball, Texas, United States
Diabetes & Endo Treatment Spec
🇺🇸Sandy, Utah, United States
Velocity Clin Res-Salt Lk City
🇺🇸West Jordan, Utah, United States
TPMG Clinical Research
🇺🇸Newport News, Virginia, United States
Rainier Clin Res Ctr Inc
🇺🇸Renton, Washington, United States
St. Vincent Hosp-Prevea Health
🇺🇸Green Bay, Wisconsin, United States
Mautalen Salud e investigación
🇦🇷Caba, Buenos Aires, Argentina
Sanatorio Güemes
🇦🇷Caba, City Of Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Rosario
🇦🇷Rosario, Santa Fe, Argentina
STAT Research
🇦🇷Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
🇦🇷Buenos Aires, Argentina
Centro de Investigación y Prevención Cardiovascular
🇦🇷Caba, Argentina
Clinical Research Facility, Charles Perkins Centre
🇦🇺Camperdown, New South Wales, Australia
Macquarie University
🇦🇺Macquarie Park, New South Wales, Australia
Hunter Diabetes Centre
🇦🇺Merewether, New South Wales, Australia
Logan Hospital
🇦🇺Meadowbrook, Queensland, Australia
Southern Adelaide Diabetes & Endocrine Services
🇦🇺Oaklands Park, South Australia, Australia
St Vincent's Hospital - Melbourne
🇦🇺Fitzroy, Victoria, Australia
Baker IDI Heart and Diabetes Institute
🇦🇺Melbourne, Victoria, Australia
Cline Research Center
🇧🇷Curitiba, Parana, Brazil
CPQuali Pesquisa Clínica Ltda
🇧🇷São Paulo, Sao Paulo, Brazil
CPCLIN - Centro de Pesquisas Clínicas
🇧🇷São Paulo, Sao Paulo, Brazil
"IPSMC - d-r Nikolay Kostadinov" EOOD
🇧🇬Burgas, Bulgaria
"Dr Tatyana Metalova - ambulatory for individual practice for specialised medical care for endocrinology" EOOD
🇧🇬Gotse Delchev, Bulgaria
Medical Center Zdrave Lom
🇧🇬Lom, Bulgaria
Medical centre Razgrad OOD
🇧🇬Razgrad, Bulgaria
Diagnostic Consulting Center Ascendent
🇧🇬Sofia, Bulgaria
"Medical Center Maraya Med" EOOD
🇧🇬Sofia, Bulgaria
Medical centre Clinic Nova
🇧🇬Varna, Bulgaria
UMHAT Sveta Marina EAD
🇧🇬Varna, Bulgaria
Centricity Research Calgary
🇨🇦Calgary, Alberta, Canada
Guilford Med Clinic
🇨🇦Surrey, British Columbia, Canada
TLC Diabetes and Endocrinology
🇨🇦Surrey, British Columbia, Canada
Ocean West Research Clinic
🇨🇦Surrey, British Columbia, Canada
Hilltop Medical Clinic
🇨🇦Surrey, British Columbia, Canada
Spectrum Health Clinic
🇨🇦Vancouver, British Columbia, Canada
G.A. Research Associates Ltd.
🇨🇦Moncton, New Brunswick, Canada
Centricity Res. Barrie Endo
🇨🇦Barrie, Ontario, Canada
Centricity Research Brampton
🇨🇦Brampton, Ontario, Canada
Centricity Research Vaughn
🇨🇦Concord, Ontario, Canada
Medical Trust Clinics, Inc.
🇨🇦Courtice, Ontario, Canada
Centricity Research Etobicoke
🇨🇦Etobicoke, Ontario, Canada
Milestone Research
🇨🇦London, Ontario, Canada
Western Univ. Cnt for Studies in Fam Med
🇨🇦London, Ontario, Canada
Centricity Research Ottawa LMC
🇨🇦Nepean, Ontario, Canada
Centricity Research Oshawa
🇨🇦Oshawa, Ontario, Canada
Centricity Research Toronto
🇨🇦Toronto, Ontario, Canada
Diabetes Heart Research Centre
🇨🇦Toronto, Ontario, Canada
Centre Medical Acadie
🇨🇦Montreal, Quebec, Canada
Centricity Res Pointe-Claire
🇨🇦Pointe-Claire, Quebec, Canada
ALPHA Recherche Clinique
🇨🇦Quebec City, Quebec, Canada
Ctr de Med Metab de Lanaudiere
🇨🇦Terrebonne, Quebec, Canada
Diex Recherche Victoriaville
🇨🇦Victoriaville, Quebec, Canada
Diex Recherche Quebec Inc.
🇨🇦Quebec, Canada
Clin des Mal Lipid de Quebec
🇨🇦Quebec, Canada
Centre de Recherche Saint-Louis
🇨🇦Quebec, Canada
Chongqing University Three Gorges Hospital
🇨🇳Chongqing, Chongqing, China
The Second Affiliated Hospital of Nanjing Medical University_Nanjing
🇨🇳Nanjing, Jiangsu, China
Suzhou Municipal Hospital
🇨🇳Suzhou, Jiangsu, China
The Affiliated Hospital of Jiangsu University_Zhenjiang
🇨🇳Zhenjiang, Jiangsu, China
Jinan Central Hospital
🇨🇳Ji'Nan, Shandong, China
Poliklinika Solmed
🇭🇷Zagreb, Grad Zagreb, Croatia
Poliklinika SLAVONIJA OSIJEK
🇭🇷Osijek, Osječko - Baranjska Županija, Croatia
KBC Rijeka, Endokrinologija
🇭🇷Rijeka, Primorsko - Goranska Županija, Croatia
Thalassotherapia Opatija
🇭🇷Opatija, Croatia
Opca bolnica Dr. Josip Bencevic
🇭🇷Slavonski Brod, Croatia
Opca bolnica Varazdin
🇭🇷Varazdin, Croatia
IKEM Centrum Diabetologie
🇨🇿Praha 4, Czech Republic, Czechia
University Hospital U sv. Anny
🇨🇿Brno, Czechia
Edumed Broumov
🇨🇿Broumov, Czechia
Diahaza s.r.o.
🇨🇿Holešov, Czechia
DIALINE s.r.o.
🇨🇿Plzeň 3, Czechia
Diabet2 s.r.o.
🇨🇿Praha 1, Czechia
MUDr. Michala Pelikanova
🇨🇿Praha 4, Czechia
Aarhus Universitetshospital, Steno Diabetes Center Aarhus
🇩🇰Aarhus N, Denmark
Steno Diabetes Center Copenhagen
🇩🇰Herlev, Denmark
Hillerød Endokrinologisk amb. H0652
🇩🇰Hillerød, Denmark
Hvidovre Hospital Endokrinologisk forsk. afs. 159
🇩🇰Hvidovre, Denmark
Bispebjerg Hospital, IC-Forskning
🇩🇰København, Denmark
Steno Diabetes Center Odense
🇩🇰Odense C, Denmark
Terveystalo Jyväskylä
🇫🇮Jyväskylä, Finland
Seinäjoen keskussairaala
🇫🇮Seinäjoki, Finland
Pihlajalinna Koskiklinikka
🇫🇮Tampere, Finland
Terveystalo Tampere Rautatienkatu
🇫🇮Tampere, Finland
Turku University Hospital
🇫🇮Turku, Finland
Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
🇩🇪Berlin, Germany
Diabetologische Schwerpunktpraxis Daaden
🇩🇪Daaden, Germany
Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
🇩🇪Dortmund, Germany
Medizinische Klinik III Studienzentrum für Stoffwechselerkrankungen der TU Dresden
🇩🇪Dresden, Germany
Zentrum fuer klinische Studien Suedbrandenburg GmbH
🇩🇪Elsterwerda, Germany
InnoDiab Forschung GmbH
🇩🇪Essen, Germany
MVZ Diabeteszentrum Dr. Tews GmbH
🇩🇪Gelnhausen, Germany
Diabetes-Zentrum-Wilhelmsburg GbR
🇩🇪Hamburg, Germany
Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR
🇩🇪Hamburg, Germany
Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz
🇩🇪Lingen, Germany
Die Praxis am Ludwigsplatz
🇩🇪Ludwigshafen, Germany
Medicover Neuroendokrinologie MVZ
🇩🇪München, Germany
RED-Institut für medizinische Forschung und Fortbildung GmbH
🇩🇪Oldenburg in Holstein, Germany
University Hospital of Athens ATTIKON
🇬🇷Haidari-Athens, Attica, Greece
General Hospital Of Thessaloniki Papageorgiou
🇬🇷Nea Efkarpia, Thessaloniki, Greece
Iatriko Psychicou Private Clinic
🇬🇷Athens, Greece
"Laiko" General Hospital of Athens
🇬🇷Athens, Greece
General hospital of Athens 'G.Gennimatas'
🇬🇷Athens, Greece
Iatriko Athinon (Athens Medical Canter)
🇬🇷Athens, Greece
Univ Gen Hospital Larisa, Endocrinology & Metabolic Disease
🇬🇷Larissa, Greece
"AHEPA" University Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
"Ippokrateio" G.H. of Thessaloniki
🇬🇷Thessaloniki, Greece
EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
🇬🇷Thessaloniki, Greece
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
🇭🇺Szeged, Csongrád-Csanád, Hungary
Debreceni Egyetem Belgyógyászati Klinika
🇭🇺Debrecen, Hajdu-Bihar, Hungary
Óbudai Egészségügyi Centrum
🇭🇺Budapest, Hungary
Bajcsy-Zsilinszky Kórház
🇭🇺Budapest, Hungary
MH Egészségügyi Központ
🇭🇺Budapest, Hungary
Kaposi Mór Oktató Kórház
🇭🇺Kaposvár, Hungary
Markusovszky Egyetemi Oktatókórház
🇭🇺Szombathely, Hungary
Yalamanchi Hospitals and Research centres pvt ltd
🇮🇳Vijaywada, Andhra Pradesh, India
Gauhati Medical College and Hospital
🇮🇳Guwahati, Assam, India
Lifecare Hospital and Research Centre
🇮🇳Bengaluru, Karnataka, India
K R Hospital
🇮🇳Mysuru, Karnataka, India
Ashirwad Hospital and Research Centre
🇮🇳Thane, Maharashtra, India
SMS Medical College & Hospital
🇮🇳Jaipur, Rajasthan, India
Madras Diabetes Research Foundation
🇮🇳Chennai, Tamil Nadu, India
Gleneagles Hospitals
🇮🇳Hyderabad, Telangana, India
Dr P V Rao - Diabetes Research Centre
🇮🇳Hyderabad, Telangana, India
Apollo Multispeciality Hospital, Kolkata
🇮🇳Kolkata, West Bengal, India
Swasthya Diabetes Care
🇮🇳Ahmedabad, India
Lady Hardinge Medical College
🇮🇳New Delhi, India
Linn clinic - Clalit Health Services
🇮🇱Haifa, Israel
Clalit sick fund Herzlia
🇮🇱Herzlia, Israel
Diabetes Clinic Wolfson MC
🇮🇱Holon, Israel
Diabetes Unit Hadassah Ein Karem MC
🇮🇱Jerusalem, Israel
Kaplan MC
🇮🇱Rehovot, Israel
Endrocrinolgy Clinic - Sheba Medical Center
🇮🇱Tel Hashomer, Israel
AOU Careggi Firenze
🇮🇹Firenze, Fi, Italy
Istituto Scientifico San Raffaele
🇮🇹Milano, MI, Italy
Azienda Sanitaria Usl Toscana Sud Est - Ospedale San Donato
🇮🇹Arezzo, Italy
Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Azienda Ospedaliero-Universitaria Renato Dulbecco
🇮🇹Catanzaro, Italy
Università degli studi G. D'Annunzio Chieti Pescara - CAST
🇮🇹Chieti Scalo, Italy
Azienda Ospedaliera Luigi Sacco
🇮🇹Milano, Italy
Azienda Ospedaliera Universitaria Federico II di Napoli
🇮🇹Napoli, Italy
AOUP Giaccone Palermo
🇮🇹Palermo, Italy
Dip. di Medicina Interna Policlinico Universitario Palermo
🇮🇹Palermo, Italy
Azienda Ospealiero Universitaria Policlinico Umberto I
🇮🇹Roma, Italy
Policlinico A. Gemelli
🇮🇹Rome, Italy
Seino Internal Medicine Clinic
🇯🇵Koriyama-shi, Fukushima, Japan, Japan
Abe Diabetes Clinic_Internal Medicine
🇯🇵Oita-shi, Oita, Japan, Japan
Akaicho Clinic
🇯🇵Chiba-shi, Chiba, Japan
Naka Kinen Clinic
🇯🇵Ibaraki, Japan
Minami Akatsuka Clinic
🇯🇵Mito-shi, Ibaraki, Japan
Medical Research Institute KITANO HOSPITAL, Diabetes & Endocrinology
🇯🇵Osaka-shi, Osaka, Japan
Tokyo-Eki Center-building Clinic
🇯🇵Tokyo, Japan
Fukuwa Clinic
🇯🇵Tokyo, Japan
The catholic university of Korea, Bucheon St.Mary's Hospital
🇰🇷Bucheon-si, Gyeonggi-do, Korea, Republic of
Yeungnam University Medical Center
🇰🇷Daegu, Korea, Republic of
Chosun University Hospital
🇰🇷Gwangju, Korea, Republic of
Kyunghee University Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Centro de investigación en Artritis y Osteoporosis S.C.
🇲🇽Mexicali, Baja California, Mexico
Centro de Investigacion Clinica Endocrinologica de Jalisco
🇲🇽Guadalajara, Jalisco, Mexico
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika
🇵🇱Lodz, Lodzkie, Poland
Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
🇵🇱Gorzow Wielkopolski, Lubuskie, Poland
Malopolskie Centrum Sercowo-Naczyniowe
🇵🇱Chrzanow, Malopolskie, Poland
Instytut Diabetologii Sp. z o.o.
🇵🇱Warszawa, Mazovian Voivodeship, Poland
Centrum Medyczne Medyk Sp. z o.o.
🇵🇱Rzeszow, Podkarpackie, Poland
Osteo Medic s.c. Artur Racewicz Jerzy Supronik
🇵🇱Bialystok, Podlaskie, Poland
NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
🇵🇱Bialystok, Podlaskie, Poland
PAKS III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
🇵🇱Tychy, Slaskie, Poland
Velocity Nova Sp. z o.o.
🇵🇱Staszow, Poland
KO-MED Centra Kliniczne Sp. z o.o.
🇵🇱Pulawy, Poland
NBR Polska Tomasz Klodawski
🇵🇱Warszawa, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
🇵🇱Warszawa, Poland
Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
🇷🇴Bucharest, Bucurestii, Romania
Spitalul Clinic Judetean Urgenta Cluj-Napoca
🇷🇴Cluj Napoca, Cluj, Romania
Diabmed Dr Popescu Alexandrina SRL
🇷🇴Ploiesti, Prahova, Romania
CMI Dr. Busegeanu Mihaela Magdalena
🇷🇴Ploiesti, Prahova, Romania
Cabinet Medical de Diabet, Nutritie si Boli Metabolice-Dr. Zaharie Daniela Gabriela
🇷🇴Zalau, Salaj, Romania
CMI Dr. Pletea Noemi SRL
🇷🇴Bacau, Romania
Mariodiab Clinic SRL
🇷🇴Brasov, Romania
Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed
🇷🇴Brasov, Romania
Diabet Med SRL
🇷🇴Bucuresti, Romania
Urodiamed SRL
🇷🇴Craiova, Romania
S.C Milena Sante SRL
🇷🇴Galati, Romania
Bella Praxis S.R.L.
🇷🇴Pascani, Romania
Poli Cardinal Med Srl
🇷🇴Reghin, Romania
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
🇷🇸Novi Sad, Vojvodina, Serbia
CHC Zvezdara, Clinical department for endocrinology
🇷🇸Belgrade, Serbia
Endocrinology, Diabetes and Metabolism Diseases Clinic
🇷🇸Belgrade, Serbia
Clinical Hospital Center Bezanijska Kosa
🇷🇸Belgrade, Serbia
Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
🇷🇸Kragujevac, Serbia
Clinical Centre Kragujevac, Internal Diseases Clinic, Endocr
🇷🇸Kragujevac, Serbia
DIADA, s.r.o.
🇸🇰Bardejov, Slovakia
Diabetologicka ambulancia DIOLI s.r.o.
🇸🇰Kosice, Slovakia
DIOLI s.r.o.
🇸🇰Kosice, Slovakia
MediVet s.r.o.
🇸🇰Malacky, Slovakia
DIALIPID, s.r.o.
🇸🇰Presov, Slovakia
MUDr. Jan Culak, s.r.o.
🇸🇰Prievidza, Slovakia
DIACENTRUM, s.r.o.
🇸🇰Ruzomberok, Slovakia
MEDI-DIA s.r.o.
🇸🇰Sabinov, Slovakia
DEImedi, s. r. o.
🇸🇰Surany, Slovakia
ARETEUS s.r.o.
🇸🇰Trebisov, Slovakia
iDia s. r. o.
🇸🇰Ziar nad Hronom, Slovakia
Healthcare centre Kocevje
🇸🇮Kocevje, Slovenia
Healthcare Centre Koper
🇸🇮Koper, Slovenia
Dermatologija Bartenjev
🇸🇮Ljubljana, Slovenia
UKC Maribor - diabetes
🇸🇮Maribor, Slovenia
Healtcare Centre Nova Gorica
🇸🇮Nova Gorica, Slovenia
Hospital Topolšica
🇸🇮Topolšica, Slovenia
Phoenix Pharma
🇿🇦Port Elizabeth, Eastern Cape, South Africa
Newtown Clinical Research
🇿🇦Johannesburg, Gauteng, South Africa
Sandton Medical Research
🇿🇦Johannesburg, Gauteng, South Africa
Clinresco Centres (Pty) Ltd
🇿🇦Kempton Park, Gauteng, South Africa
Clinical Trial Systems (CTC)
🇿🇦Pretoria, Gauteng, South Africa
Paarl Research Centre
🇿🇦Paarl, Western Cape, South Africa
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Complejo Hospitalario Universitario A Coruña
🇪🇸La Coruña, Spain
ABS La Roca del Vallés
🇪🇸La Roca del Vallés, Spain
Hospital Universitario de Móstoles
🇪🇸Móstoles, Spain
Hospital Son Llatzer
🇪🇸Palma de Mallorca, Spain
Hospital General de Segovia
🇪🇸Segovia, Spain
Hospital Infanta Luisa
🇪🇸Sevilla, Spain
Hospital La Fe - Endocrinología y Nutrición
🇪🇸Valencia, Spain
Clemenstorgets Hjärtmottagning
🇸🇪Lund, Sweden
Forskningsmottagning Internmedicin (tidigare KFE)
🇸🇪Malmö, Sweden
CTC GoCo Mölndal
🇸🇪Mölndal, Sweden
Karolinska Universitetssjukhuset Solna,FOU Tema Hjärta Kärl
🇸🇪Stockholm, Sweden
Överviktsenheten Örebro universitetssjukhus
🇸🇪Örebro, Sweden
Changhua Christian Hospital
🇨🇳Changhua City, Taiwan
Taipei Medical University Hospital
🇨🇳Taipei city, Taiwan
Cukurova Universitesi Tip Fakultesi
🇹🇷Adana, Turkey
Akdeniz University Tip Fakultesi Hastanesi
🇹🇷Antalya, Turkey
Eskisehir Osmangazi University School of Medicine
🇹🇷Eskisehir, Turkey
Haseki Sultangazi
🇹🇷Istanbul, Turkey
Seyrantepe Hamidiye Etfal Egitim ve Arastirma Hastanesi
🇹🇷Istanbul, Turkey
Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji
🇹🇷Istanbul, Turkey
Basaksehir Cam ve Sakura Sehir Hastanesi
🇹🇷Istanbul, Turkey
T.C SB Goztepe Prof. Dr. Suleyman Yalcin City Hospital
🇹🇷Istanbul, Turkey
Recep Tayyip Erdoğan Üni. Eğitim ve Araştırma Hastanesi
🇹🇷Rize, Turkey
Tekirdag Namık Kemal UTF
🇹🇷Tekirdag, Turkey
Lister Hospital
🇬🇧Stevenage, Hertfordshire, United Kingdom
Aberdeen Royal Infirmary
🇬🇧Foresterhill, United Kingdom
Oldfield Surgery
🇬🇧Bath, United Kingdom
Oakenhurst Surgery
🇬🇧Blackburn, United Kingdom
Ninewells Hospital
🇬🇧Dundee, United Kingdom
University Hospital Aintree
🇬🇧Liverpool, United Kingdom
Norfolk and Norwich University Hospital Trust
🇬🇧Norwich, United Kingdom
Pickering Medical Practice
🇬🇧Pickering, United Kingdom
Moorgreen Hospital
🇬🇧Southampton, United Kingdom
Joint Clinical Research Facility - Swansea
🇬🇧Swansea, United Kingdom
Royal Cornwall Hospital (Treliske)
🇬🇧Truro, United Kingdom